Archynetys Live news trend intelligence
◼ Archived Business 🔮 Archynetys predicts: fades by tomorrow — graded ✓ correct

FDA approves Replimune melanoma drug previously rejected twice

Replimune's melanoma drug wins FDA approval on third attempt, but stock price falls.

By · Published August 9, 2026  10:51 UTC · Updated August 10, 2026  22:27 UTC

9sources
11articles
8velocity
+0%since first seen
64d agofirst detected
Text:
🤖 AI Dossier

Evidence dossier

Intelligence passport

85/100 Exceptional
9distinct sources shown
40velocity measurements
1language editions checked
All brief claims passed the second-source checkbrief evidence status

Measured timeline

📍 Aftermath

The FDA approved Replimune's melanoma drug Tudriqev, following two previous rejections. The drug was approved for use in combination with Nivolumab for advanced cutaneous melanoma.

Epilogue added 62d ago, after coverage quieted.

How fast it spread

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

What happened

⚡ Executive Intelligence Takeaways Corroborated across 9 independent newsrooms
  • Velocity & Diffusion: Coverage exploded across 9 distinct news outlets with 11 published articles, achieving a live velocity of 8.
  • Primary Driver: Replimune's melanoma drug wins FDA approval on third attempt, but stock price falls.
  • Predictive Outlook: Archynetys algorithmic models forecast this story will fade from trending status over the next 24 hours.
  • Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.

The FDA has approved Replimune's melanoma drug Tudriqev. The drug is approved for use in combination with Nivolumab for treating unresectable advanced cutaneous melanoma. The approval comes after two prior rejections and a yearlong regulatory battle. The FDA approval is accelerated. The drug's approval was first reported by Yahoo Finance and Reuters. The approval was also covered by BioPharma Dive, Endpoints News, Fierce Pharma, and the Wall Street Journal. The approval was also covered by Barron's, which noted that Replimune's stock price fell 11% after hours.

The stock price drop was also reported by Yahoo Finance. STAT News covered the approval in two articles. The first article was a roundup of pharmaceutical news. The second article was a standalone piece on the approval. Barron's and Yahoo Finance both noted that Replimune's stock price fell after the approval. The reason for the drop is not specified in coverage. The stock price drop was not mentioned in other outlets.

The drug is approved for use in combination with Nivolumab. The drug is approved for treating unresectable advanced cutaneous melanoma. The drug was approved after two prior rejections and a yearlong regulatory battle. The FDA approval is accelerated. The stock price fell 11% after hours.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 62d ago.

Sources (11)

Questions people are asking

What is the name of the approved drug?

The approved drug is called Tudriqev.

What is the drug approved for?

The drug is approved for treating unresectable advanced cutaneous melanoma.

How many times was the drug rejected before approval?

The drug was rejected twice before approval.

📊 AUDIENCE & LONGEVITY PULSE

How do you expect this trend to evolve over the next 24 hours?

Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.

Select an assessment to vote. Verified Reader Intelligence

Topics

Replimune FDA Tudriqev Melanoma Drug Approval Nivolumab

Related trends

Open prediction lab

Can you beat the machine?

Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.

Make a prediction →